Matt Bochenek received his BS in Industrial and Enterprise Systems Engineering from the University of Illinois Urbana/Champaign. His interest in biological systems made him alter his focus, and he pursued a Ph.D. in Bioengineering at the University of Illinois at Chicago (UIC). Here, he worked with Dr. Jose Oberholzer in a Phase III clinical trial for intraportal islet transplantation. This entails isolating insulin producing islet cells from human donor pancreata and transplanting them intraportally into Type I diabetic patients in order to restore glycemic control. Currently, he works as a senior post-doc in Dr. Dan Anderson and Dr. Bob Langer labs at MIT. and works for cell and. Matt's work primarily focuses on the development of immunomodulatory biomaterials, specifically for the immuno-protection of islet cells and other cell-based therapies, as well for cancer therapies. Recently, he published in Nature BME to show that anti-fibrotic alginate modified materials can protect islet cells in non-human primates for up to 4 months without the need for immunosuppression.